Literature DB >> 35762437

[Expression of thyroglobulin antibody and thyroid peroxidase antibody in children with immune thrombocytopenia].

Xue-Mei Wang1, Hailigulli Nuriddin1, Yu Liu1, Gulibaha Maimaiti1, Mei Yan1.   

Abstract

OBJECTIVES: To examine the expression of serum thyroglobulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) in children with immune thrombocytopenia (ITP).
METHODS: A total of 120 children with ITP who were admitted from October 2019 to October 2021 were enrolled as the ITP group. A total of 60 children without ITP were enrolled as the non-ITP group. According to the clinical classification of ITP, the children in the ITP group were further divided into a newly diagnosed ITP group, a persistent ITP group, and a chronic ITP group. The clinical data were compared between the ITP group and the non-ITP group and between the children with different clinical classifications of ITP. The expression levels of serum TGAb and TPOAb in children with ITP were measured and their association with the clinical classification of ITP was analyzed.
RESULTS: Compared with the non-ITP group, the ITP group had significantly lower levels of CD3+, CD4+, and platelet count (PLT) and significantly higher levels of CD8+, TGAb, and TPOAb (P<0.05). The children with chronic ITP had significantly lower levels of CD3+, CD4+, and PLT and significantly higher levels of CD8+, TGAb, and TPOAb than those with newly diagnosed ITP or persistent ITP (P<0.05). The logistic regression analysis showed that CD3+, CD4+, CD8+, TGAb, and TPOAb were the influencing factors for chronic ITP (P<0.05). A decision curve was plotted, and the results showed that TGAb combined with TPOAb within the high-risk threshold range of 0.0-1.0 had a net benefit rate of >0 in evaluating the clinical classification of ITP in children.
CONCLUSIONS: TGAb and TPOAb are abnormally expressed in children with ITP and are associated with the clinical classification of ITP in children.

Entities:  

Keywords:  Child; Clinical classification; Immune thrombocytopenia; Thyroglobulin antibody; Thyroid peroxidase antibody

Mesh:

Substances:

Year:  2022        PMID: 35762437      PMCID: PMC9250402          DOI: 10.7499/j.issn.1008-8830.2112150

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  10 in total

1.  Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Authors:  Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert
Journal:  Am J Hematol       Date:  2018-05-06       Impact factor: 10.047

2.  Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia.

Authors:  Mingqiang Hua; Ju Li; Chunyan Wang; Linlin Shao; Ming Hou; Jun Peng; Qi Feng
Journal:  Thromb Res       Date:  2019-03-05       Impact factor: 3.944

3.  Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children.

Authors:  Liqiong Yao; Bei Liu; Li Jiang; Lanxia Zhou; Xiaoju Liu
Journal:  Hematology       Date:  2018-10-14       Impact factor: 2.269

4.  The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted analysis of 5-year results of a prospective non-randomized bi-center study.

Authors:  Sanwei Guo; Georg Müller; Kurt Lehmann; Scherwin Talimi; Gernot Bonkat; Heike Püschel; Thomas Gasser; Alexander Bachmann; Malte Rieken
Journal:  Lasers Med Sci       Date:  2015-02-20       Impact factor: 3.161

5.  Predicting the Risk of Graves Disease Relapse: Commentary on "Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease".

Authors:  D Gallo; M L Tanda; E Piantanida
Journal:  Endocr Pract       Date:  2020-09       Impact factor: 3.443

6.  Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis.

Authors:  S Fernández-Plaza; J González de Pablo; E Gálvez; J Zubicaray; M Guillén; J Sevilla; E Sebastián
Journal:  Eur J Pediatr       Date:  2021-02-16       Impact factor: 3.183

Review 7.  Fostamatinib for persistent/chronic adult immune thrombocytopenia.

Authors:  Adrian Newland; Eun-Ju Lee; Vickie McDonald; James B Bussel
Journal:  Immunotherapy       Date:  2017-10-02       Impact factor: 4.196

8.  Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer?

Authors:  S Hosseini; R J Payne; F Zawawi; A Mlynarek; M P Hier; M Tamilia; V I Forest
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-05-14

9.  Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia.

Authors:  Qian Wang; Juan Li; Tian-Shu Yu; Yu Liu; Kai Li; Shuang Liu; Yang Liu; Qi Feng; Lei Zhang; Guo-Sheng Li; Lin-Lin Shao; Jun Peng; Ming Hou; Xin-Guang Liu
Journal:  Int J Biol Sci       Date:  2019-10-23       Impact factor: 6.580

10.  Development and validation of an ELISA for a biomarker of thyroid dysfunction, thyroid peroxidase autoantibodies (TPO-Ab), in dried blood spots.

Authors:  Geeta N Eick; Tara J Cepon-Robins; Maureen J Devlin; Paul Kowal; Larry S Sugiyama; J Josh Snodgrass
Journal:  J Physiol Anthropol       Date:  2020-07-16       Impact factor: 2.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.